Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges

Dados Bibliográficos

ID15375333
AutoresAndré Luis Gemal (Universidade Federal do Rio de Janeiro), Andre Gemal, Joel Keravec, Alexandre Menezes, Anete Trajman (0000-0002-4000-4984, McGill University, autor correspondente)
Ano2013
Volume13
Fascículo1
Páginas279-279
Data de publicação2013-03-27
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoBMC Public Health (JOURNAL)
Identificadores do periódicoISSN: 1471-2458 • E-ISSN: 1471-2458
EditoraBioMed Central (PUBLISHER • GB)
DOI10.1186/1471-2458-13-279
PMID23537151
PMCIDPMC3645962
OpenAlexW2166947801
IdiomaEN
Referências citadas12

International manufacturers of raw material for tuberculosis treatment should undergo certification and pre-qualify their active pharmaceutical ingredients as a first step to ensure quality of tuberculosis drugs. At the country level, Brazilian public manufacturers should apply for international certification and tuberculosis drugs should be pre-qualified by international organisms. Finally, only with political commitment and large-scale production will Brazilian public sector manufacturers be able to partially supply the global market

Certification · Environmental health · Public health · Quality (philosophy · Risk analysis (engineering · Tuberculosis · Biotechnology and Related Fields · Global Health and Surgery · Medicine · Tuberculosis Research and Epidemiology